Reduced cerebrospinal fluid estradiol levels are associated with increased beta-amyloid levels in female patients with Alzheimer's disease.
Recent in-vitro studies indicate that estrogens such as 17beta-estradiol (E2) may decrease the production of beta-amyloid 1-42 (Abeta42), a peptide central for the formation of senile plaques in Alzheimer's disease (AD). To test this hypothesis in a clinical study, cerebrospinal fluid levels of E2 were compared between 30 female AD patients and 11 female patients with non-dementing diseases such as major depression and investigated with respect to beta-amyloid 1-40 and Abeta42 levels. E2 levels were significantly (P<0.05) lower in the AD group than in controls; within the AD group E2 levels were inversely correlated with Abeta42 concentrations (r=-0.36, P=0.05). This is the first clinical study providing evidence for an influence of E2 on Abeta42 metabolism in vivo. This observation corresponds to the putative beneficial effects of estrogen replacement therapy on the development and course of AD.
Schönknecht
P
P
Section of Geriatric Psychiatry, Department of Psychiatry, University of Heidelberg, Voss-Strasse 4, D-69115, Heidelberg, Germany.
Pantel
J
J
Klinga
K
K
Jensen
M
M
Hartmann
T
T
Salbach
B
B
Schröder
J
J
D000368:Aged; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid* / Q000473:pathology / Q000503:physiopathology; D016229:Amyloid beta-Peptides / Q000096:biosynthesis / Q000134:cerebrospinal fluid*; D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D004958:Estradiol / Q000134:cerebrospinal fluid*; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D008593:Menopause / Q000378:metabolism; D018696:Neuroprotective Agents / Q000378:metabolism*; D012737:Sex Factors
D016229:Amyloid beta-Peptides; D018696:Neuroprotective Agents; D004958:Estradiol